Subcutaneous Botulinum Toxin for Cutaneous Allodynia.

Trial Profile

Subcutaneous Botulinum Toxin for Cutaneous Allodynia.

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Oct 2017

At a glance

  • Drugs Botulinum toxin A (Primary)
  • Indications Neuropathic pain
  • Focus Therapeutic Use
  • Sponsors Allergan
  • Most Recent Events

    • 03 May 2014 Status changed from active, no longer recruiting to completed.
    • 03 May 2014 Primary endpoint 'Time-to-treatment-failure' has not been met.
    • 03 May 2014 Results presented at the 33rd Annual Scientific Meeting of the American Pain Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top